CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
Enrolling by invitation · NCT06605833 · Registry updated 2025-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, cardiovascular disorder, heart disorder, injury, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, radiation injury, skin disorder, skin neoplasm | Enrolling by invitation | Not stated | 2025-10-01 | NCT06605833 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Royal Brompton & Harefield NHS Foundation Trust | 38 |
| Royal Free Hospital NHS Foundation Trust | 36 |
| Royal Marsden NHS Foundation Trust | 89 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Royal Marsden NHS Foundation Trust | London | United Kingdom | 1 |